These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

701 related items for PubMed ID: 22892337

  • 1. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study.
    Sandborn WJ, Travis S, Moro L, Jones R, Gautille T, Bagin R, Huang M, Yeung P, Ballard ED.
    Gastroenterology; 2012 Nov; 143(5):1218-1226.e2. PubMed ID: 22892337
    [Abstract] [Full Text] [Related]

  • 2. Oral budesonide for induction of remission in ulcerative colitis.
    Sherlock ME, MacDonald JK, Griffiths AM, Steinhart AH, Seow CH.
    Cochrane Database Syst Rev; 2015 Oct 26; 2015(10):CD007698. PubMed ID: 26497719
    [Abstract] [Full Text] [Related]

  • 3. Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies.
    Sandborn WJ, Danese S, D'Haens G, Moro L, Jones R, Bagin R, Huang M, David Ballard E, Masure J, Travis S.
    Aliment Pharmacol Ther; 2015 Mar 26; 41(5):409-18. PubMed ID: 25588902
    [Abstract] [Full Text] [Related]

  • 4. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study.
    Travis SP, Danese S, Kupcinskas L, Alexeeva O, D'Haens G, Gibson PR, Moro L, Jones R, Ballard ED, Masure J, Rossini M, Sandborn WJ.
    Gut; 2014 Mar 26; 63(3):433-41. PubMed ID: 23436336
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial.
    Rubin DT, Cohen RD, Sandborn WJ, Lichtenstein GR, Axler J, Riddell RH, Zhu C, Barrett AC, Bortey E, Forbes WP.
    J Crohns Colitis; 2017 Jul 01; 11(7):785-791. PubMed ID: 28333362
    [Abstract] [Full Text] [Related]

  • 7. Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX® 9 mg extended-release tablets in patients with active left-sided ulcerative colitis.
    D'Haens GR, Kovács A, Vergauwe P, Nagy F, Molnár T, Bouhnik Y, Weiss W, Brunner H, Lavergne-Slove A, Binelli D, Di Stefano AF, Marteau P.
    J Crohns Colitis; 2010 Jun 01; 4(2):153-60. PubMed ID: 21122499
    [Abstract] [Full Text] [Related]

  • 8. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
    Kamm MA, Sandborn WJ, Gassull M, Schreiber S, Jackowski L, Butler T, Lyne A, Stephenson D, Palmen M, Joseph RE.
    Gastroenterology; 2007 Jan 01; 132(1):66-75; quiz 432-3. PubMed ID: 17241860
    [Abstract] [Full Text] [Related]

  • 9. Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis.
    Miehlke S, Madisch A, Kupcinskas L, Petrauskas D, Böhm G, Marks HJ, Neumeyer M, Nathan T, Fernández-Bañares F, Greinwald R, Mohrbacher R, Vieth M, Bonderup OK, BUC-60/COC Study Group.
    Gastroenterology; 2014 May 01; 146(5):1222-30.e1-2. PubMed ID: 24440672
    [Abstract] [Full Text] [Related]

  • 10. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
    Lichtenstein GR, Kamm MA, Boddu P, Gubergrits N, Lyne A, Butler T, Lees K, Joseph RE, Sandborn WJ.
    Clin Gastroenterol Hepatol; 2007 Jan 01; 5(1):95-102. PubMed ID: 17234558
    [Abstract] [Full Text] [Related]

  • 11. Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis.
    Danese S, Siegel CA, Peyrin-Biroulet L.
    Aliment Pharmacol Ther; 2014 May 01; 39(10):1095-103. PubMed ID: 24641622
    [Abstract] [Full Text] [Related]

  • 12. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials.
    Sandborn WJ, Kamm MA, Lichtenstein GR, Lyne A, Butler T, Joseph RE.
    Aliment Pharmacol Ther; 2007 Jul 15; 26(2):205-15. PubMed ID: 17593066
    [Abstract] [Full Text] [Related]

  • 13. Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis.
    Lichtenstein GR.
    Dig Dis Sci; 2016 Feb 15; 61(2):358-70. PubMed ID: 26541989
    [Abstract] [Full Text] [Related]

  • 14. Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis.
    D'Haens G, Sandborn WJ, Barrett K, Hodgson I, Streck P.
    Am J Gastroenterol; 2012 Jul 15; 107(7):1064-77. PubMed ID: 22565161
    [Abstract] [Full Text] [Related]

  • 15. Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis.
    Bonovas S, Nikolopoulos GK, Piovani D, González-Lorenzo M, Pantavou K, Lytras T, Peyrin-Biroulet L, Danese S.
    Br J Clin Pharmacol; 2019 Oct 15; 85(10):2244-2254. PubMed ID: 31269287
    [Abstract] [Full Text] [Related]

  • 16. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis.
    Kamm MA, Lichtenstein GR, Sandborn WJ, Schreiber S, Lees K, Barrett K, Joseph R.
    Inflamm Bowel Dis; 2009 Jan 15; 15(1):1-8. PubMed ID: 18671232
    [Abstract] [Full Text] [Related]

  • 17. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
    Lichtenstein GR, Kamm MA, Sandborn WJ, Lyne A, Joseph RE.
    Aliment Pharmacol Ther; 2008 Jun 01; 27(11):1094-102. PubMed ID: 18363894
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of prolonged release budesonide granules in mesalazine-refractory ulcerative colitis: A multi-centre Phase IIa study (TOPICAL-1).
    Fellermann K, Schiefke I, Rácz I, Derova J, Jonaitis L, Wehrum S, Nacak T, Greinwald R.
    United European Gastroenterol J; 2020 Dec 01; 8(10):1186-1195. PubMed ID: 33028169
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.